President Donald Trump, now serving his second term, has announced a new series of federal agreements aimed at significantly reducing the cost of obesity medications and expanding their coverage under Medicare. The policy, unveiled during a White House press briefing on Thursday, marks a major shift in the government’s approach to treating obesity — a condition that affects more than 40% of American adults.
The deal that will lower the cost and expand Medicare coverage of certain obesity drugs is expected to take effect early next year. It will include negotiated price reductions with major pharmaceutical companies and streamlined approval pathways for new anti-obesity treatments. The administration described the move as part of its broader effort to “make lifesaving medications more affordable and accessible to seniors and working families.”
Trump Administration Partners With Drugmakers to Broaden Access
President Trump announced new deals that will bring several pharmaceutical firms into direct collaboration with the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). The deal that will lower the cost and expand Medicare coverage of certain obesity drugs will reportedly include leading products such as Wegovy, Ozempic, and Mounjaro — medications known for both weight management and cardiovascular benefits.
Officials say the arrangement will allow Medicare to negotiate bulk pricing, potentially cutting patient out-of-pocket costs by up to 40%. Under the terms of the new policy, physicians will also have greater flexibility in prescribing these drugs, while health insurers will be mandated to include at least one anti-obesity drug on their covered medication lists. Trump framed the initiative as “a victory for seniors and for every American fighting to live a healthier life without being priced out by big pharma.”
Public Health Experts Applaud Move but Urge Broader Action
President Trump announced new deals that could, according to health economists, reshape how chronic diseases related to obesity are treated in the U.S. The deal that will lower the cost and expand Medicare coverage of certain obesity drugs has drawn praise from medical associations who have long argued that obesity should be treated as a chronic condition rather than a lifestyle issue.
However, some experts cautioned that affordability alone will not solve the broader public health crisis. “Lower prices are a great start, but access also depends on education, nutrition programs, and ongoing medical support,” said Dr. Lisa Mendoza, a public health policy analyst at Johns Hopkins University. The administration, meanwhile, hinted that further health reforms could be announced before the end of the year, including expanded coverage for diabetes prevention and cardiovascular health initiatives.
President Trump’s new Medicare deals represent one of the administration’s most ambitious healthcare moves since taking office for a second term. With obesity-related conditions costing the U.S. over $170 billion annually, the policy could deliver both economic relief and improved quality of life for millions of Americans. Whether it marks a turning point in the nation’s fight against obesity will depend on how effectively the policy is implemented in the coming months.
